Nicholas Goulden
Overview
Explore the profile of Nicholas Goulden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moorman A, Antony G, Wade R, Butler E, Enshaei A, Harrison C, et al.
J Clin Oncol
. 2022 Jun;
40(36):4228-4239.
PMID: 35714315
Purpose: The aim of the randomized trial, UKALL2003, was to adjust treatment intensity on the basis of minimal residual disease (MRD) stratification for children and young adults with acute lymphoblastic...
2.
Ghorashian S, Kramer A, Onuoha S, Wright G, Bartram J, Richardson R, et al.
Nat Med
. 2019 Sep;
25(9):1408-1414.
PMID: 31477906
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL), but toxicity, including cytokine-release syndrome (CRS) and neurotoxicity, limits broader application. Moreover, 40-60%...
3.
Sellar R, Rowntree C, Vora A, Furness C, Goulden N, Mitchell C, et al.
Br J Haematol
. 2018 Apr;
181(4):515-522.
PMID: 29687881
Outcomes for teenage and young adult (TYA) patients with acute lymphoblastic leukaemia (ALL) who relapse on contemporary risk-adapted paediatric protocols are largely unknown and there is no consensus on optimal...
4.
Farah N, Kirkwood A, Rahman S, Leon T, Jenkinson S, Gale R, et al.
Haematologica
. 2018 Mar;
103(7):e288-e292.
PMID: 29519867
No abstract available.
5.
Furness C, Kirkwood A, Rowntree C, Vora A, Mitchell C, Samarasinghe S, et al.
Br J Haematol
. 2018 Feb;
184(4):663-666.
PMID: 29468646
No abstract available.
6.
Tan R, Ganau M, Jeelani N, Tahir Z, Mankad K, Kachramanoglou C, et al.
Br J Haematol
. 2016 Jun;
178(4):642-645.
PMID: 27353525
No abstract available.
7.
Morgenstern D, Ahsan G, Brocklesby M, Ings S, Balsa C, Veys P, et al.
Br J Haematol
. 2016 Jun;
174(6):942-51.
PMID: 27291859
Standard quality assurance (QA) of cryopreserved peripheral blood stem cells (PBSC) uses post-thaw viable CD34(+) cell counts. In 2013, concerns arose at Great Ormond Street Hospital (GOSH) about 8 patients...
8.
van der Sluis I, Vrooman L, Pieters R, Baruchel A, Escherich G, Goulden N, et al.
Haematologica
. 2016 Mar;
101(3):279-85.
PMID: 26928249
L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern...
9.
Schwab C, Ryan S, Chilton L, Elliott A, Murray J, Richardson S, et al.
Blood
. 2016 Feb;
127(18):2214-8.
PMID: 26872634
The EBF1-PDGFRB gene fusion accounts for <1% of B-cell precursor acute lymphoblastic leukemia (ALL) cases and occurs within the Philadelphia-like ALL subtype. We report 15 EBF1-PDGFRB-positive patients from childhood ALL...
10.
Vora A, Andreano A, Pui C, Hunger S, Schrappe M, Moericke A, et al.
J Clin Oncol
. 2016 Jan;
34(9):919-26.
PMID: 26755523
Purpose: We sought to determine whether cranial radiotherapy (CRT) is necessary to prevent relapse in any subgroup of children with acute lymphoblastic leukemia (ALL). Patients And Methods: We obtained aggregate...